– Neuralstem Announces Publication of Data From First-In-Human Study of Human Neural Stem Cell Transplantation for Chronic Spinal Cord Injury –
– First cohort of four subjects with thoracic (T2-T12) ASIA-A grade spinal cord injury in the Phase I study
Geneva, May 23, 2018 (GLOBE NEWSWIRE) — The governments of Cambodia, China, the Lao People’s Democratic Republic, Myanmar, Thailand and Viet Nam have together called for accelerated action to eliminate malaria in the Greater Mekong Subregion (GMS) by 2030.
Signing
MALTA, May 02, 2018 (GLOBE NEWSWIRE) — DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for DRGT-99, an innovative formulation of tadalafil.
Tadalafil (Cialis®) was originally developed by
Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 ≥25% and <25% groups in 2nd-line non-small cell lung cancer
Phase I Study 10 data shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinoma
CAMBRIDGE, United Kingdom,
GERMANTOWN, Md., April 11, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem, will be providing a clinical update at the Alliance
